Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-22-008159
Filing Date
2022-04-01
Accepted
2022-04-01 16:09:51
Documents
9
Period of Report
2022-05-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A sgmo_proxyx2022xdef.htm DEF 14A 1352334
2 GRAPHIC hrdiversitychartsidebyside.jpg GRAPHIC 85359
3 GRAPHIC macraesignaturea02.jpg GRAPHIC 28251
4 GRAPHIC sangamo-2021cdagraphicfact.jpg GRAPHIC 116239
5 GRAPHIC sangamo-2021cdagraphicprim.jpg GRAPHIC 128981
6 GRAPHIC sangamo-2022cdagraphiccash.jpg GRAPHIC 108065
7 GRAPHIC sangamo-2022cdagraphicceo2.jpg GRAPHIC 65158
8 GRAPHIC sgmoproxycardp1.jpg GRAPHIC 131766
9 GRAPHIC sgmoproxycardp2.jpg GRAPHIC 98345
  Complete submission text file 0001628280-22-008159.txt   2387968
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-30171 | Film No.: 22798303
SIC: 2836 Biological Products, (No Diagnostic Substances)